About this trial
This study aims to explore the imaging and electrophysiological characteristics of idiopathic inflammatory demyelinating diseases (IIDDs), and their correlation with clinical manifestations. It also evaluates the effectiveness of transcranial electrical stimulation in alleviating clinical symptoms of IIDDs patients, and analyzes the key factors affecting the treatment efficacy. By uncovering the overall and individual characteristics of IIDDs, this study seeks to enhance therapeutic outcomes through personalized neuromodulation programs. The findings will provide a basis for applying non-invasive brain stimulation (NIBS) in IIDDs treatment and offer new ideas for future personalized medicine approaches.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age: 18-60 years old.
Diagnosis: Patients with neuromyelitis optica spectrum disease, multiple sclerosis and other inflammatory demyelinating diseases of the central nervous system that meet the diagnostic criteria.
Medications have been stable for at least three months.
Disqualifiers
Recurrence has been recorded in the past 3 months.
Have a pacemaker or other metal implant in the body.
Impaired skin integrity at the site of electrode placement.
Previous organic brain disease such as epilepsy, hydrocephalus, central nervous system tumors, brain injury, or intracranial infection.
Trial design
Parallel
Treatments tested in this trial
Neuroelectrical modulation group
DeviceParticipants received transcranial electrical stimulation using the Spanish Neuroelectrics StarStim 32 device.
Pseudo-neuromodulation group
DevicePseudo-stimulation is performed using the same equipment and procedures as in the neuromodulation group.
Treatment groups
Trial outcomes
Primary outcomes
Expanded Disability Status Scale, EDSS score
0-10 points, the higher the score, the more serious
Symbol Digit Modalities Test (SDMT) scale
0-110 points, the higher the score, the better the cognitive function
Scoring results for tasks 1 and 7 in the Alzheimer disease assessment scale-cog(ADAS-cog)
the higher the score, the better the cognitive function
Secondary outcomes
Mini-mental State Examination(MMSE)
0-30,the higher the score, the better the cognitive function
Montreal-Cognitive Assessment(MoCA)
0-30,the higher the score, the better the cognitive function
Stroop Color-Word Test score
the higher the score, the better the cognitive function
Hamilton Depression Scale,HAMD
The higher the score, the worse the depression.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.